# Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

> **NCT00669136** · PHASE1 · TERMINATED · sponsor: **Lisa H. Butterfield, Ph.D.** · enrollment: 2 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatoma
- Liver Cancer, Adult
- Liver Cell Carcinoma
- Liver Cell Carcinoma, Adult
- Cancer of Liver
- Cancer of the Liver
- Cancer, Hepatocellular
- Hepatic Cancer
- Hepatic Neoplasms
- Hepatocellular Cancer
- Liver Cancer
- Neoplasms, Hepatic
- Neoplasms, Liver

## Interventions

- **DRUG:** AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost

## Key facts

- **NCT ID:** NCT00669136
- **Lead sponsor:** Lisa H. Butterfield, Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor accrual and limited target patient population for future accrual. Did not complete the Phase 1 portion of the trial.
- **Last updated:** 2015-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00669136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00669136, "Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00669136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*